Global Peripheral Myelin Protein 22 (PMP22) Gene Related Disorder Market, By Disease Type (Charcot-Marie-Tooth Disease Type IA, Dejerine-Sottas Syndrome, Hereditary Neuropathy), Treatment (Gabapentin, Amitriptyline, Analgesics, Others), Diagnosis (Clinical Examination, Muscle Biopsy, Genetic Testing, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Peripheral Myelin Protein 22 (PMP22) Gene Related Disorder Market Analysis and Size
The rise in the inherited peripheral neuropathies will act as major driver that will results in the expansion of market’s growth. Another significant factor influencing the growth rate of peripheral myelin protein 22 (PMP22) gene related disorder market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, rising initiatives by public and private organisations to spread awareness and growing government funding are the factors that will expand the peripheral myelin protein 22 (PMP22) gene related disorder market. Other factors such as increase in the demand for effective therapies and rising adoption rate of early geriatric counselling will positively impact the peripheral myelin protein 22 (PMP22) gene related disorder market’s growth rate. In addition, high disposable income and changing lifestyle will result in the expansion of peripheral myelin protein 22 (PMP22) gene related disorder market.
Data Bridge Market Research analyzes that the peripheral myelin protein 22 (PMP22) gene related disorder market which was USD 157.20 million in 2022, would rocket up to USD 288.74 million by 2030, and is expected to undergo a CAGR of 4.8% during the forecast period. This indicates that the market value. “Hospitals” dominates the end user segment of the peripheral myelin protein 22 (PMP22) gene related disorder market due to the increasing awareness among the population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Disease Type (Charcot-Marie-Tooth Disease Type IA, Dejerine-Sottas Syndrome, Hereditary Neuropathy), Treatment (Gabapentin, Amitriptyline, Analgesics, Others), Diagnosis (Clinical Examination, Muscle Biopsy, Genetic Testing, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), Sanofi (France), Aurobindo Pharma (India), Mylan N.V. (Netherlands), GlaxoSmithKline plc (U.K.), Cipla Inc. (India), Sun Pharmaceutical Industries Ltd. (India), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), Eli Lilly and Company (U.S.), Lupin (India), Reckitt Benckiser Group PLC (U.K.), Endo International plc (Ireland), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany)
|
|
Market Opportunities
|
|
Market Definition
Peripheral Myelin Protein 22 (PMP22) gene-related disorders refer to a group of genetic conditions that are associated with abnormalities or mutations in the PMP22 gene. The PMP22 gene provides instructions for the production of a protein called peripheral myelin protein 22, which plays a crucial role in the formation and maintenance of myelin, a fatty substance that surrounds and insulates nerve fibers.
Peripheral Myelin Protein 22 (PMP22) Gene Related Disorder Market Dynamics
Drivers
- Advancements in Genetic Research
Growing advancements in genetic research techniques, including gene sequencing and editing, enable a better understanding of the PMP22 gene. This leads to the development of targeted therapies. Advancements in genetic research techniques, particularly in sequencing and gene editing technologies, have significantly contributed to understanding the PMP22 gene, leading to potential therapeutic interventions.
- Increasing prevalence of neuropathies
The rising incidence of neuropathies and neurological disorders, where mutations in the PMP22 gene play a role, drives research and development in therapies targeting this gene. Deeper understanding of diseases associated with PMP22 mutations has led to increased focus on developing targeted therapies and personalized medicine approaches.
- Rising prevalence of neuropathies
The increasing incidence of neuropathies and genetic disorders, including those associated with the PMP22 gene, fuels research and development efforts for effective treatments.
Opportunities
- Targeted therapies
Advances in targeted therapies, including gene therapies and gene editing techniques, present an opportunity to develop specific treatments addressing the root cause of diseases related to the PMP22 gene.
- Patient advocacy and awareness
Increasing awareness about genetic disorders and supporting patient advocacy groups can drive research funding, public support, and policy changes conducive to genetic research.
Restraints/Challenges
- Complex genetic interactions
The genetic basis of neuropathies involving the PMP22 gene is often complex, involving multiple genes and pathways, making therapeutic interventions challenging
- Limited therapeutic options
Current treatment options for genetic disorders related to the PMP22 gene are limited and often focus on symptom management rather than addressing the underlying genetic cause.
This peripheral myelin protein 22 (PMP22) gene related disorder market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the peripheral myelin protein 22 (PMP22) gene related disorder market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Peripheral Myelin Protein 22 (PMP22) Gene Related Disorder Market Scope
The peripheral myelin protein 22 (PMP22) gene related disorder market is segmented on the basis of disease type, treatment, diagnosis, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Disease type
- Charcot-marie-tooth disease type IA
- Dejerine-sottas syndrome and hereditary neuropathy
Treatment
- Gabapentin
- Amitriptyline
- Analgesics
- Others.
Diagnosis
- Clinical examination
- Muscle Biopsy
- Genetic testing
- Others.
Dosage
- Injection
- tablets
- Others
Route of administration
- Oral
- Intravenous
- Others
End users
- Hospitals
- Clinics
- Others
Peripheral Myelin Protein 22 (PMP22) Gene Related Disorder Market Regional Analysis/Insights
he peripheral myelin protein 22 (PMP22) gene related disorder market is analyZed and market size insights and trends are provided by country, product type, drug class, type of manufacturing, procedure, disease, indication, therapy type and end users as referenced above.
The countries covered in the peripheral myelin protein 22 (PMP22) gene related disorder market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.
North America is expected to dominate the market due to the strong base of healthcare facilities, availability of reimbursements, rising geriatric population, high healthcare spending and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increasing patient pool, rising investment in the healthcare sector and growing government support in the region
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
peripheral myelin protein 22 (PMP22) gene related disorder market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for peripheral myelin protein 22 (PMP22) gene related disorder market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the peripheral myelin protein 22 (PMP22) gene related disorder market. The data is available for historic period 2010-2020.
Competitive Landscape and Peripheral Myelin Protein 22 (PMP22) Gene Related Disorder Market Share Analysis
The peripheral myelin protein 22 (PMP22) gene related disorder market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to peripheral myelin protein 22 (PMP22) gene related disorder market.
Some of the major players operating in the peripheral myelin protein 22 (PMP22) gene related disorder market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- AbbVie Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Sanofi (France)
- Aurobindo Pharma (India)
- Mylan N.V. (Netherlands)
- GlaxoSmithKline plc (U.K.)
- Cipla Inc. (India)
- Sun Pharmaceutical Industries Ltd. (India)
- Abbott (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Merck & Co., Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Lupin (India)
- Reckitt Benckiser Group PLC (U.K.)
- Endo International plc (Ireland)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
SKU-